Fate Therapeutics Inc (FATE)
3.80
-0.07
(-1.81%)
USD |
NASDAQ |
Apr 26, 16:00
3.795
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Research and Development Expense (Quarterly): 31.82M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 31.82M |
| September 30, 2023 | 34.28M |
| June 30, 2023 | 40.88M |
| March 31, 2023 | 65.63M |
| December 31, 2022 | 87.19M |
| September 30, 2022 | 79.82M |
| June 30, 2022 | 81.31M |
| March 31, 2022 | 72.14M |
| December 31, 2021 | 69.52M |
| September 30, 2021 | 53.13M |
| June 30, 2021 | 48.02M |
| March 31, 2021 | 44.85M |
| December 31, 2020 | 38.98M |
| September 30, 2020 | 30.69M |
| June 30, 2020 | 26.67M |
| March 31, 2020 | 29.28M |
| December 31, 2019 | 25.21M |
| September 30, 2019 | 23.20M |
| June 30, 2019 | 21.63M |
| March 31, 2019 | 17.73M |
| December 31, 2018 | 14.10M |
| September 30, 2018 | 13.64M |
| June 30, 2018 | 16.82M |
| Date | Value |
|---|---|
| March 31, 2018 | 11.48M |
| December 31, 2017 | 9.887M |
| September 30, 2017 | 8.578M |
| June 30, 2017 | 7.927M |
| March 31, 2017 | 7.966M |
| December 31, 2016 | 6.23M |
| September 30, 2016 | 6.804M |
| June 30, 2016 | 6.782M |
| March 31, 2016 | 6.636M |
| December 31, 2015 | 5.433M |
| September 30, 2015 | 5.003M |
| June 30, 2015 | 4.857M |
| March 31, 2015 | 4.568M |
| December 31, 2014 | 3.865M |
| September 30, 2014 | 4.08M |
| June 30, 2014 | 3.968M |
| March 31, 2014 | 4.522M |
| December 31, 2013 | 3.031M |
| September 30, 2013 | 3.378M |
| June 30, 2013 | 3.067M |
| March 31, 2013 | 2.531M |
| December 31, 2012 | 3.403M |
| September 30, 2012 | 3.315M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
21.63M
Minimum
Jun 2019
87.19M
Maximum
Dec 2022
47.59M
Average
40.88M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 35.03M |
| Regeneron Pharmaceuticals Inc | 1.177B |
| Sarepta Therapeutics Inc | 195.52M |
| ADMA Biologics Inc | 0.4455M |
| Ocular Therapeutix Inc | 16.20M |